Figure 5.

Time course of E₂ supplementation and ERr 731 replacement therapy in OVX rats. (A) Schematic diagram of the replacement strategy. (B) In the dark phase, the E₂ treatment of OVX rats significantly reduced T_skin from experimental day 10 (day 2 of E₂ treatment) through the end of the study. In rats that received ERr 731 therapy, the effect remained significant at high doses (3 mg/kg/day) and reached significance on several days at middle dose (1 mg/kg/day) through the end of the study. (C) Overall average T_skin was significantly increased in OVX rats and reduced following either E₂ (0.3 mg/kg/day) or ERr 731 replacement therapy (1–3 mg/kg/day) for the duration of the treatment. Data are the mean ± SEM (n = 6), * p < 0.05 vs. OVX control.